{
    "clinical_study": {
        "@rank": "67279", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Active Comparator", 
                "description": "Jaundiced patients with bilirubin value >80 \u03bcmol/L. Received G17DT immediately prior to biliary stenting."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients to be treated following biliary decompression or for immediate treatment if non-jaundiced. Received G17DT 2 weeks after biliary stenting when bilirubin was <40 \u03bcmol/L."
            }
        ], 
        "brief_summary": {
            "textblock": "The study was designed to assess the effect of jaundice on the ability of G17DT to generate\n      antibodies before and after treatment of biliary obstruction due to advances pancreatic\n      cancer."
        }, 
        "brief_title": "Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.", 
        "completion_date": "May 2002", 
        "condition": [
            "Jaundice", 
            "Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Jaundice", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Jaundiced patients with advanced pancreatic cancer (either locally, advanced or metastatic)\n      were treated with G17DT either immediately (Group A), or following biliary stenting when\n      jaundice had resolved (Group B). Patients not jaundiced at time of presentation were to\n      enter Group B. Patients received 3 Intramuscular injections of G17DT at weeks 0, 1, and 3. A\n      booster injection was offered to patients who had measurable anit-G17Dt antibodies but had\n      anti-G17DT antibodies that fell below a pre-specified threshold after week 23. Patients were\n      evaluated until study closure ort until patient death."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a pancreatic adenocarcinoma (cytologically or histologically proven),\n             not suitable for a potentially curative resection.\n\n          -  If patients were jaundiced, bilirubin had to be >80 \u03bcmol/L.\n\n          -  Male or female patients over 18 years of age.\n\n          -  World Health Organization (WHO) performance status of 0 to 2.\n\n          -  Patients with a life expectancy of at least 8 weeks.\n\n          -  Patients must have given written informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients undergoing a potentially curative resection.\n\n          -  Jaundiced patients with a bilirubin value <80 \u03bcmol/L.\n\n          -  Patients not considered fit for endoscopic or percutaneous biliary stenting.\n\n          -  Patients receiving any other anti-cancer therapy.\n\n          -  History of other malignant disease except non-melanomatous skin cancer or in situ\n             carcinoma of the cervix.\n\n          -  Females who were pregnant, planning to become pregnant, or who were lactating.\n\n          -  Patients taking part in another study involving an investigational or licensed drug\n             or device in the three months preceding enrolment or during this study.\n\n          -  Previous G17DT treatment.\n\n          -  Haematological indicators:\n\n        Haemoglobin (Hb) <10.0 g/dL. White cell count (WCC) <4.0\u00d7109/L. Platelets <100\u00d7109/L."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "id_info": {
            "nct_id": "NCT02098239", 
            "org_study_id": "PC2"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B"
            ], 
            "intervention_name": "G17DT", 
            "intervention_type": "Drug", 
            "other_name": "Polyclonal Antibody Stimulator (PAS)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "lastchanged_date": "March 25, 2014", 
        "official_title": "An Open, Multiple Dose, Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Gastrin-17 antibodies were measured at baseline (Week 0) and measured at each post-treatment visit.", 
                "measure": "Pharmacodynamic", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 1,3,4,6,8,12, 16+"
            }, 
            {
                "description": "The vital status of patients was monitored throughout the study and was followed until death or the end of the study.", 
                "measure": "Patient Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to week 139"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098239"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tolerability was assessed by injection site during first 16 weeks after the first injection.", 
            "measure": "Injection Tolerability", 
            "safety_issue": "No", 
            "time_frame": "Up to Week 16"
        }, 
        "source": "Cancer Advances Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cancer Advances Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 1999", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}